Frontlight ResearchEarly access
Active, not recruitingNo phase
Long-term Follow-Up for RGX-121
Key facts
- Who runs it
- REGENXBIO Inc.
- Where
- New Brunswich, Philadelphia, and San Francisco, United StatesSee the 3 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 27 people enrolled
- Started
- 14 Mar 2021
- Expected to end
- Oct 2028
- Type of study
- Observational
- Treatments tested
- Long-term Follow-Up
- Record updated
- 19 August 2026
Who can take part
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- To be eligible, a participant must have previously received RGX-121 in a separate parent trial
- Participant or participant's legal guardian(s) is/(are) willing and able to provide written, signed informed consent
Who cannot take part
- Participant has not received RGX-121 previously in a separate parent trial
Where in United States
Also in 1 other country, 1 site
- Saint Peter's Healthcare SystemNew Brunswich, United States
- The Children's Hospital of Philadelphia (CHOP)Philadelphia, United States
- University of California, San Francisco (UCSF) Benioff Children's HospitalSan Francisco, United States
About the trial
What the trial wants to find out
RGX-121-5101 is an observational long-term follow-up study to the RGX-121-101 or RGX-121-1102 studies where participants received RGX-121, a gene therapy intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study will evaluate the long-term safety and efficacy of RGX-121.
The group in the trial
- Long-term Follow-Up
No intervention.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-121
- Record updated
- 19 August 2026